The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to provide input into the Texas Board of Pharmacy’s (Board) strategic planning process for fiscal years 2019-2023. As the profession of pharmacy continues to evolve and the role of pharmacists expand from dispensers of medications to direct care providers, so too must Board requirements.
The Academy of Managed Care Pharmacy (AMCP) thanks the Office of Disease Prevention and Health Promotion (ODPHP) for the opportunity to provide comments on the Healthy People 2030 Draft Framework. AMCP appreciates the leadership of ODPHP on the Healthy People initiative to improve the health and wellbeing of Americans, an initiative that AMCP has been supportive of since its inception.
The Academy of Managed Care Pharmacy (AMCP) thanks the Arkansas State Board of Pharmacy (Board) for the opportunity to provide comments on the proposed changes to Regulation 7 – Drug Products/Prescriptions as they relate to biosimilar products.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the request for comments titled “Administering the HatchWaxman Amendments: Ensuring a Balance Between Innovation and Access [Docket No. FDA–2017–N–3615]” as published in the Federal Register on June 22, 2017.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in response to the solicitation of public comments on biosimilars included in the proposed rule “Medicare Program; Revisions to Payment Policies under the Physician Fee Schedule and Other Revisions to Part B for CY 2018 [Docket No. CMS-1676-P]” as published in the Federal Register on July 21, 2017.
AMCP joins a coalition of over 35 health care stakeholders committed to aligning 42 CFR part 2 (part 2) with HIPAA to allow appropriate access to patient information that is essential for providing whole-person care.
The Academy of Managed Care Pharmacy (AMCP) thanks the Institute of Clinical and Economic Review (ICER) for the opportunity to provide comments on the “Potential Topics for Review in 2018” released on July 26, 2017. AMCP applauds ICER for considering new and emerging therapies, as well as incorporating public feedback, into the development of a robust review agenda for 2018.